Core Viewpoint - The article highlights the insufficient public awareness of scientific smoking cessation methods, particularly regarding cessation medications, despite the existence of effective options and guidelines from WHO [1][12]. Group 1: Smoking Cessation Medications - WHO's first clinical treatment guideline for adult smoking cessation identifies three main types of medications: varenicline, nicotine replacement therapy (NRT), and bupropion [1][12]. - Varenicline is a first-line medication with four domestic companies having approved generic versions, yet sales were below 100 million yuan last year [1][12]. - The sales of varenicline in China have not met expectations, with Pfizer's original product experiencing a significant decline due to safety concerns [1][18]. Group 2: Challenges in Smoking Cessation - Nearly 60% of smokers abandon cessation attempts due to withdrawal symptoms, with a success rate of less than 5% for those relying solely on willpower [7][8]. - The understanding of cessation medications among both smokers and healthcare professionals remains limited, contributing to low utilization rates [13][17]. - The lack of awareness and the absence of these medications in insurance coverage are identified as major barriers to effective smoking cessation [20]. Group 3: Market Trends and Opportunities - The retail market for varenicline is projected to grow significantly, with sales expected to reach 48 million yuan in 2024, reflecting a growth rate exceeding 2000% [20][21]. - Online platforms like JD Health report a more than twofold increase in sales of smoking cessation medications, indicating a shift towards digital health solutions [20]. - The market share of companies like Qianyuan Pharmaceutical in the retail sector is notably high, suggesting potential for further expansion in the smoking cessation market [20][21].

Group 1 - The "2025 Smoking Control and Cessation White Paper" reveals that 73.1% of smokers use traditional cigarettes, while 26.9% use e-cigarettes, with 85.8% smoking 11-20 cigarettes daily, indicating a significant prevalence of smoking in the population [1][2] - The report highlights that 58.7% of smokers consider quitting for health reasons, and 79.3% believe that medication can effectively assist in quitting, showing a strong recognition of the role of pharmacological aids in smoking cessation [1][3] Group 2 - The success rate of smoking cessation attempts in China is below 10%, emphasizing the need for scientific methods and professional guidance to improve outcomes [2][3] - The white paper suggests seven effective strategies for quitting smoking, including setting a quit plan, seeking support from friends and family, and using professional help or medications [4] Group 3 - A one-stop smoking cessation health management platform is being developed by JD Health in collaboration with industry partners to address issues such as lack of awareness and inadequate management in smoking cessation [5] - The user base for smoking cessation medications on JD Health has been growing rapidly, with a compound annual growth rate exceeding 246%, indicating a rising demand for these products [3]